Study type

Study topic

DiseaseĀ /health condition

Study type

Non-interventional study

Scope of the study

Disease epidemiology

Data collection methods

Secondary use of data
Non-interventional study

Non-interventional study design

Cohort
Study drug and medical condition

Medical condition to be studied

Retinal artery occlusion
Age-related macular degeneration

Additional medical condition(s)

Specifically neovascular age-related macular degeneration
Population studied

Short description of the study population

The study included age-related macular degeneration (nAMD) population assessed annually from 2000 to 2018 identified from the IMRD-UK (formerly known as THIN) database.

Age groups

Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Special population of interest

Other

Special population of interest, other

Patients with retinal artery occlusion and age-related macular degeneration

Estimated number of subjects

5000
Study design details

Main study objective

To establish the incidence of recorded central Retinal Artery Occlusion in the general (IMRD-UK) population stratified by age, sex and smoking status.

Outcomes

Central Retinal Artery Occlusion, Other Retinal Artery Occlusion

Data analysis plan

Incidence rates will be calculated as the number of incident cases of RAO divided by the total population follow up time and is described as the event rate per 100,000 person years (PY). This will be stratified by age category, sex and smoking status. To allow comparison with previous incidence studies, incidence rates will be applied to the 1976 European reference population. To establish the expected event rate in the nAMD population, event rates will be applied to the nAMD population stratified by age & sex, and age, sex & smoking status. Confidence intervals for all standardised incidence rates will be calculated using the approach of Greenland et al (Introduction to Stratified Analysis. In Modern Epidemiology). The actual rate of cRAO in the nAMD population will be calculated as the incidence number of cases divided by the patient years at risk during follow-up, although it is anticipated numbers will be low.
Documents
Study results
English (513.55 KB - PDF)View document